BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1286 related articles for article (PubMed ID: 34467980)

  • 21. Associations of metal mixtures with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2003-2018.
    Xie Z; Aimuzi R; Si M; Qu Y; Jiang Y
    Front Public Health; 2023; 11():1133194. PubMed ID: 36950101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between serum 25-hydroxy vitamin D concentrations and mortality among individuals with metabolic dysfunction-associated fatty liver disease: a prospective cohort study.
    Zhang JJ; Yu HC; Li Y; Zhang YB; Geng TT; Lu Q; Liao YF; Guo KQ; Du L; Ruan HL; Yang K; Liu G; Pan A
    Am J Clin Nutr; 2022 Nov; 116(5):1409-1417. PubMed ID: 36107812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
    Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX
    World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fatty liver with metabolic disorder, such as metabolic dysfunction-associated fatty liver disease, indicates high risk for developing diabetes mellitus.
    Miyake T; Matsuura B; Furukawa S; Ishihara T; Yoshida O; Miyazaki M; Watanebe K; Shiomi A; Nakaguchi H; Yamamoto Y; Koizumi Y; Tokumoto Y; Hirooka M; Takeshita E; Kumagi T; Abe M; Ikeda Y; Iwata T; Hiasa Y
    J Diabetes Investig; 2022 Jul; 13(7):1245-1252. PubMed ID: 35167194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early-Life Exposure to Famine and Risk of Metabolic Associated Fatty Liver Disease in Chinese Adults.
    Liu J; Wang G; Wu Y; Guan Y; Luo Z; Zhao G; Jiang Y
    Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults.
    Liu J; Ayada I; Zhang X; Wang L; Li Y; Wen T; Ma Z; Bruno MJ; de Knegt RJ; Cao W; Peppelenbosch MP; Ghanbari M; Li Z; Pan Q
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e573-e582. PubMed ID: 33618024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study.
    Chen J; Dan L; Tu X; Sun Y; Deng M; Chen X; Hesketh T; Li R; Wang X; Li X
    Hepatol Int; 2023 Feb; 17(1):202-214. PubMed ID: 36194337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of cardiovascular mortality between MAFLD and NAFLD: A cohort study.
    Yoo TK; Lee MY; Kim SH; Zheng MH; Targher G; Byrne CD; Sung KC
    Nutr Metab Cardiovasc Dis; 2023 May; 33(5):947-955. PubMed ID: 36746687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study.
    Lee H; Lee HW; Kim SU; Chang Kim H
    Clin Transl Gastroenterol; 2022 Jan; 13(1):e00435. PubMed ID: 35080508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease.
    Wong VW; Wong GL; Woo J; Abrigo JM; Chan CK; Shu SS; Leung JK; Chim AM; Kong AP; Lui GC; Chan HL; Chu WC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2161-2171.e5. PubMed ID: 33137486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased risk of incident diabetes in patients with MAFLD not meeting the criteria for NAFLD.
    Park SH; Park J; Kwon SY; Lee YB; Kim G; Hur KY; Koh J; Jee JH; Kim JH; Kang M; Jin SM
    Sci Rep; 2023 Jul; 13(1):10677. PubMed ID: 37393407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic dysfunction-associated fatty liver disease as a risk factor for adverse outcomes in subsequent pregnancy: a nationwide cohort study.
    Lee SM; Cho GJ; Wi WY; Norwitz ER; Koo BK; Lee J; Jung YM; Kwak SH; Park CW; Jun JK; Joo SK; Oh MJ; Kim W; Park JS
    Hepatol Int; 2023 Apr; 17(2):367-376. PubMed ID: 36542262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NAFLD and MAFLD as emerging causes of HCC: A populational study.
    Myers S; Neyroud-Caspar I; Spahr L; Gkouvatsos K; Fournier E; Giostra E; Magini G; Frossard JL; Bascaron ME; Vernaz N; Zampaglione L; Negro F; Goossens N
    JHEP Rep; 2021 Apr; 3(2):100231. PubMed ID: 33748726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
    Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
    Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
    Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease.
    Wu T; Ye J; Shao C; Li F; Lin Y; Ma Q; Wang W; Feng S; Zhong B
    Front Endocrinol (Lausanne); 2021; 12():691556. PubMed ID: 34899591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.
    Nguyen VH; Le MH; Cheung RC; Nguyen MH
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2172-2181.e6. PubMed ID: 34033923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study.
    Kemp W; Clayton-Chubb D; Majeed A; Glenister KM; Magliano DJ; Lubel J; Bourke L; Simmons D; Roberts SK
    J Gastroenterol Hepatol; 2022 Feb; 37(2):395-403. PubMed ID: 34693553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic dysfunction-associated fatty liver disease increases the risk of type 2 diabetes mellitus in young Korean adults.
    Ha J; Hong OK; Han K; Kwon HS
    Diabetes Res Clin Pract; 2024 Jun; 212():111584. PubMed ID: 38367650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.